Tasigna (nilotinib) is a popular cancer drug that is used to treat chronic myeloid leukemia. Manufactured and marketed by Novartis, Tasigna has been linked to severe and life-threatening side effects. Tasigna complications include rapid-onset and irreversible atherosclerosis, leading to peripheral arterial disease. Simply put, Tasigna causes the body's arteries to become narrowed, leading to tissue death, limb amputation, cardiovascular complications, and even death.
Tasigna side effects lawsuits aim to hold Novartis accountable for the harm its drug has caused, and to provide meaningful compensation to persons and families who have suffered Tasigna complications. Tasigna problems lawyers believe that persons and the families of persons harmed by Tasigna side effects may be eligible for significant compensation through filing a claim against Novartis. This page provides full information about Tasigna side effects from national Tasigna attorneys.
Tasigna is a protein-tyrosine kinase inhibitor used to treat Philadelphia chromosome-positive chronic myeloid leukemia. One of the ten most sold cancer drugs in the world, Tasigna was first approved in the United States in 2007. At that time, Tasigna was accompanied by a Black Box FDA warning but it did not include information about the Tasigna atherosclerosis. Tasigna prevents growth and cell division in cancer cells by blocking the production of a particular chemical enzyme. Tasigna is an effective treatment for chronic myeloid leukemia, yet its cardiovascular risks may outweigh its benefits.
Tasigna atherosclerosis is characterized by a proliferation of white blood cells and a buildup of fibrofatty plaque in the arteries. This condition results in increasingly thick arterial walls and shrinking channels for blood to flow. Narrowing arteries, a condition known as peripheral arterial disease, often affect the legs first but can impact the functioning of other arteries. Tasigna atherosclerosis impedes the flow of blood to the extremities, resulting in tissue death and infection possibly requiring limb amputation. Tasigna atherosclerosis complications also include coronary artery disease, other cardiovascular problems and death.
Thousands upon thousands of American patients have taken Tasigna with the belief that the drug was safe and effective. Countless doctors have prescribed the drug with no knowledge of its life-threatening side effects. Novartis has known of these Tasigna complications since at least 2011, though has never formally warned the American public.
On the contrary, the company funded aggressive and even illegal marketing campaigns aimed at boosting Tasigna sales. In 2013, Novartis paid $390 million to settle a lawsuit with the U.S. Department of Justice in which the company was accused of paying illegal kickbacks to pharmacies who sold Tasigna over generic versions. The company also came under scrutiny in 2010 for violating federal regulations. The FDA sent Novartis a Cease and Desist order for misbranding; Novartis advertising in the U.S. relied on unproven claims that Tasigna was more effective than alternatives.
Our attorneys specialize in holding large corporations accountable when they've placed profits ahead of safety. Through settlements and winning verdicts, our attorneys have obtained millions for our clients. Let us help you today.
Filing a lawsuit will allow you to hold the pharmaceutical company accountable for damage it has caused you or a loved one, while also providing real compensation for your medical expenses, suffering and loss. Contact us today for a free consultation.